Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

Relationship Between Symptoms, Retinal Morphology, and the Nigrostriatal Dopamine System in Parkinson's Disease
Relationship Between Symptom Severity, Retinal Morphology, and the Nigrostriatal Dopamine System in the Brain in Parkinson's Disease
Status: Enrolling
Updated:  10/12/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Relationship Between Symptoms, Retinal Morphology, and the Nigrostriatal Dopamine System in Parkinson's Disease
Relationship Between Symptom Severity, Retinal Morphology, and the Nigrostriatal Dopamine System in the Brain in Parkinson's Disease
Status: Enrolling
Updated: 10/12/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effect of Osteopathic Manipulative Medicine (OMM) on Pulmonary Function and Speech in Parkinson's Disease
Effect of Osteopathic Manipulative Medicine on Pulmonary Function and Speech in Parkinson's Disease
Status: Enrolling
Updated:  10/13/2017
NYIT NYCOM Academic Health Care Center
mi
from
Old Westbury, NY
Effect of Osteopathic Manipulative Medicine (OMM) on Pulmonary Function and Speech in Parkinson's Disease
Effect of Osteopathic Manipulative Medicine on Pulmonary Function and Speech in Parkinson's Disease
Status: Enrolling
Updated: 10/13/2017
NYIT NYCOM Academic Health Care Center
mi
from
Old Westbury, NY
Click here to add this to my saved trials
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated:  10/24/2017
Keck School of Medicine
mi
from
Los Angeles, CA
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated: 10/24/2017
Keck School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated:  10/24/2017
Neurosearch, Inc.
mi
from
Reseda, CA
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated: 10/24/2017
Neurosearch, Inc.
mi
from
Reseda, CA
Click here to add this to my saved trials
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated:  10/24/2017
Parkinson's Disease and Movement Disorders Center of Boca Raton
mi
from
Boca Raton, FL
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated: 10/24/2017
Parkinson's Disease and Movement Disorders Center of Boca Raton
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated:  10/24/2017
Rush University Medical Center
mi
from
Chicago, IL
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated: 10/24/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated:  10/24/2017
Henry Ford West Bloomfield Hospital
mi
from
Bloomfield Hills, MI
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated: 10/24/2017
Henry Ford West Bloomfield Hospital
mi
from
Bloomfield Hills, MI
Click here to add this to my saved trials
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated:  10/24/2017
Parkinson's Disease and Movement Disorders Center of New York
mi
from
Commack, NY
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated: 10/24/2017
Parkinson's Disease and Movement Disorders Center of New York
mi
from
Commack, NY
Click here to add this to my saved trials
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated:  10/24/2017
University of Cincinnati Academic Health Center
mi
from
Cincinnati, OH
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated: 10/24/2017
University of Cincinnati Academic Health Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated:  10/24/2017
The Movement Disorder Clinic of Oklahoma
mi
from
Tulsa, OK
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated: 10/24/2017
The Movement Disorder Clinic of Oklahoma
mi
from
Tulsa, OK
Click here to add this to my saved trials
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated:  10/24/2017
University of Texas Health Science Center, Houston, Department of Neurology
mi
from
Houston, TX
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated: 10/24/2017
University of Texas Health Science Center, Houston, Department of Neurology
mi
from
Houston, TX
Click here to add this to my saved trials
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated:  10/24/2017
Center for Neurological Care and Research
mi
from
San Antonio, TX
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated: 10/24/2017
Center for Neurological Care and Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated:  10/24/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated: 10/24/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated:  10/24/2017
Georgetown University
mi
from
Washington, D.C.,
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Status: Enrolling
Updated: 10/24/2017
Georgetown University
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Comparison of Cardiorespiratory Fitness Among Regular Exercisers With and Without Parkinson Disease and Across Different Modes of Group Exercise
Comparison of Cardiorespiratory Fitness Among Regular Exercisers With and Without Parkinson Disease and Across Different Modes of Group Exercise
Status: Enrolling
Updated:  10/24/2017
University of Indianapolis
mi
from
Indianapolis, IN
Comparison of Cardiorespiratory Fitness Among Regular Exercisers With and Without Parkinson Disease and Across Different Modes of Group Exercise
Comparison of Cardiorespiratory Fitness Among Regular Exercisers With and Without Parkinson Disease and Across Different Modes of Group Exercise
Status: Enrolling
Updated: 10/24/2017
University of Indianapolis
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Birmingham
mi
from
Birmingham, AL
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Los Angeles
mi
from
Los Angeles, CA
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Aurora
mi
from
Aurora, CO
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Manchester
mi
from
Manchester, CT
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Manchester
mi
from
Manchester, CT
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site New Haven
mi
from
New Haven, CT
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site New Haven
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Boca Raton
mi
from
Boca Raton, FL
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Boca Raton
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Port Charlotte
mi
from
Port Charlotte, FL
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Port Charlotte
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Tampa
mi
from
Tampa, FL
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Augusta
mi
from
Augusta, GA
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Augusta
mi
from
Augusta, GA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 site Chicago
mi
from
Chicago, IL
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 site Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Kansas City
mi
from
Kansas City, KA
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Kansas City
mi
from
Kansas City, KA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Boston
mi
from
Boston, MA
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Golden Valley
mi
from
Golden valley, MN
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Golden Valley
mi
from
Golden valley, MN
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Camden
mi
from
Camden, NJ
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Camden
mi
from
Camden, NJ
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site New Brunswick
mi
from
New Brunswick, NJ
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site New Brunswick
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 site Commack
mi
from
Commack, NY
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 site Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site New York
mi
from
New York, NY
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site New York
mi
from
New York, NY
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Durham
mi
from
Durham, NC
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Durham
mi
from
Durham, NC
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Cincinnati
mi
from
Cincinnati, OH
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Toledo
mi
from
Toledo, OH
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Toledo
mi
from
Toledo, OH
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Tulsa
mi
from
Tulsa, OK
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Houston
mi
from
Houston, TX
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Roanoke
mi
from
Roanoke, VA
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Roanoke
mi
from
Roanoke, VA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site west Bloomfield
mi
from
West Bloomfield Township, MI
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site west Bloomfield
mi
from
West Bloomfield Township, MI
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated:  10/30/2017
P2B001 Site Asaf Harofe
mi
from
Beer Yakov,
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Enrolling
Updated: 10/30/2017
P2B001 Site Asaf Harofe
mi
from
Beer Yakov,
Click here to add this to my saved trials
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease
Status: Enrolling
Updated:  10/31/2017
UCLA Neurology
mi
from
Los Angeles, CA
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease
Status: Enrolling
Updated: 10/31/2017
UCLA Neurology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
Effects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation (DBS) Electrode Implantation Surgery
Status: Enrolling
Updated:  11/6/2017
University of Wisconsin - Madison, School of Medicine and Public Health
mi
from
Madison, WI
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
Effects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation (DBS) Electrode Implantation Surgery
Status: Enrolling
Updated: 11/6/2017
University of Wisconsin - Madison, School of Medicine and Public Health
mi
from
Madison, WI
Click here to add this to my saved trials
CUSTOM-DBS: Current Steering to Optimize Deep Brain Stimulation
Current Steering to Optimize Deep Brain Stimulation
Status: Enrolling
Updated:  11/14/2017
Boston Scientific Clinical Research Information Toll Free Number
mi
from
Valencia, CA
CUSTOM-DBS: Current Steering to Optimize Deep Brain Stimulation
Current Steering to Optimize Deep Brain Stimulation
Status: Enrolling
Updated: 11/14/2017
Boston Scientific Clinical Research Information Toll Free Number
mi
from
Valencia, CA
Click here to add this to my saved trials
CUSTOM-DBS: Current Steering to Optimize Deep Brain Stimulation
Current Steering to Optimize Deep Brain Stimulation
Status: Enrolling
Updated:  11/14/2017
Universitat Wurzburg
mi
from
Wurzburg,
CUSTOM-DBS: Current Steering to Optimize Deep Brain Stimulation
Current Steering to Optimize Deep Brain Stimulation
Status: Enrolling
Updated: 11/14/2017
Universitat Wurzburg
mi
from
Wurzburg,
Click here to add this to my saved trials
Double-blind Placebo Surgery Trial for Treatment of Parkinson's Disease
Transplantation of Embryonic Dopamine Neurons for Treatment of Parkinson's Disease: Double-blind Placebo Surgery Trial
Status: Enrolling
Updated:  11/15/2017
Morgridge College of Education, University of Denver
mi
from
Denver, CO
Double-blind Placebo Surgery Trial for Treatment of Parkinson's Disease
Transplantation of Embryonic Dopamine Neurons for Treatment of Parkinson's Disease: Double-blind Placebo Surgery Trial
Status: Enrolling
Updated: 11/15/2017
Morgridge College of Education, University of Denver
mi
from
Denver, CO
Click here to add this to my saved trials
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Boston, MA
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
New York, NY
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Tulsa, OK
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Sun City, AZ
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Sun City, AZ
Click here to add this to my saved trials